Compare Recursion Pharmaceuticals Inc (RXRX) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Thomson Reuters Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B), while Thomson Reuters Corp trades at $102.17 (market cap $45.38B). The key difference: Thomson Reuters Corp is far larger — about 25.1× Recursion Pharmaceuticals Inc's market cap, and Thomson Reuters Corp pays a 2.5% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | TRI | |
|---|---|---|
Market Cap | $1.81B | $45.38B |
Sector | Health | Industrials |
52-Week High | $6.79 | $178.77 |
52-Week Low | $2.84 | $76.55 |
Enterprise Value | $1.33B | $48.00B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Thomson Reuters (TRI) trades at $102.46, down 1.82% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $0.99, beating estimates, and raised full-year revenue guidance, driven by 8% organic growth in its Legal, Corporates, and Tax segments. Valuation metrics show a P/E of 27.61 and net income margin of 21.22%, with strong profitability and a dividend yield supported by recent $0.66 payouts.
Outlook remains positive due to robust recurring revenue and AI-driven product momentum, though risks include execution challenges in technology integration and competitive pressures. Analysts project a 29.8% upside to the consensus price target of $124.00, with 52% recommending Buy. Investors should weigh solid fundamentals against macroeconomic and sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
